Goodwin Procter and Wilson Sonsini Goodrich & Rosati represented MBX Biosciences, Inc. in the offering, and Davis Polk & Wardwell represented the underwriters. MBX Biosciences, Inc....
MBX Biosciences’ $187.7 Million IPO
Pathos AI’s Acquisition of Rain Oncology
Leerink Partners is acting as exclusive financial advisor and Gibson, Dunn & Crutcher LLP is acting as legal counsel to Rain. Goodwin Procter LLP is acting...
LENZ Therapeutics’ Merger with Graphite Bio
Wilson Sonsini Goodrich & Rosati is representing LENZ Therapeutics in the transaction, Goodwin Procter is representing Graphite Bio and Latham & Watkins is representing the placements...
Kyowa Kirin’s $387 Million Acquisition of Orchard Therapeutics
Kyowa Kirin was represented by Goldman Sachs Japan Co., Ltd. as financial advisor and Morrison & Foerster LLP. as legal advisor. Orchard Therapeutics was represented by...
Closed Loop Medicine’s Global Co-Development Partnership with Pharmanovia
Goodwin advised Closed Loop Medicine on the deal. Closed Loop Medicine Ltd and Pharmanovia announced that they have entered a global co-development partnership. The partnership will initially...
Tay’s License Agreement with VYNE Therapeutics
Goodwin advised Tay on the agreement. Tay entered into a license agreement with VYNE Therapeutics, under which VYNE obtained exclusive rights to Tay’s oral BET inhibitor, TAY-B2...
FibroGen’s $150 Million Financing with Morgan Stanley Tactical Value
Goodwin Procter acted as counsel to FibroGen, and Gibson Dunn acted as counsel to Morgan Stanley Tactical Value. FibroGen, Inc. (NASDAQ: FGEN) announced a non-dilutive term...
Magenta Therapeutics’ Merger with Dianthus Therapeutics
Gibson, Dunn & Crutcher LLP acted for Dianthus Therapeutics, Inc. on its merger with Magenta Therapeutics, Inc., assisted by Goodwin Procter. Magenta Therapeutics, Inc. (Nasdaq: MGTA) and Dianthus Therapeutics,...
STALICLA’s In-Licensing Agreement with Novartis
Goodwin Procter advised STALICLA SA on the deal. STALICLA SA announced its exclusive in-licensing agreement with Novartis to develop mavoglurant as a treatment for substance-use disorder, neurodevelopmental...
STALICLA’s In-licensing of SFX-01
Goodwin Procter advised STALICLA on the deal. STALICLA announced its worldwide in-licensing of SFX-01, a patented composition of synthetic sulforaphane and alpha-cyclodextrin, from Evgen Pharma in neurodevelopmental...
Insempra’s Investment into Solena Materials
Goodwin Procter advised Insempra on the deal. Insempra announced its strategic investment into Solena Materials Ltd (“Solena”) a synthetic biology company. Solena, a spin-out from Imperial College...
Gilead Sciences’ $405 Million Acquisition of MiroBio
Davis Polk & Wardwell, Mayer Brown, and Mishcon de Reya advised Gilead, while Goodwin Procter and Wilson Sonsini Goodrich & Rosati advised MiroBio on the deal....